There is a history of studying relaxin in cardiovascular settings—Novartis started a phase 3 heart failure trial of a recombinant relaxin-2 peptide in 2013—but preclinical evidence of the molecule’s ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth-quarter 2025 investor letter. It is a diversified fund that focuses on long-term capital appreciation by ...

The company's shares rose 11% in the fourth quarter to close at 137.90 pounds on Dec. 31.

The pharmaceutical giant announced profit in line with expectations and revenue that slightly beat forecasts on Tuesday.

By Pushkala Aripaka, Bhanvi Satija and Maggie Fick LONDON, Feb 10 (Reuters) - AstraZeneca forecast steady profit growth in ...

The COVID-19 vaccine participant whose unexpected illness put the AstraZeneca trials on pause came down with an inflammatory syndrome known as transverse myelitis, according to a report. The ...

AstraZeneca's shares jumped after Pfizer's announcement of a major deal with the Trump administration. Pfizer's good news could benefit AstraZeneca, too. Pfizer CEO Albert Bourla appeared with ...

Carillon Tower Advisers, an investment management company, released its fourth-quarter 2025 investor letter “Carillon Eagle Growth & Income Fund”. A copy of the letter can be downloaded here. 2025 ...

AstraZeneca, the U.K.-Swedish pharmaceutical giant, on Tuesday announced a plan to invest some $50 billion in the U.S. in a move hailed by the Trump administration - though much of what it is ...

Add Yahoo as a preferred source to see more of our stories on Google. A U.S. flag stands next to the AstraZeneca logo in Washington, D.C. By Maggie Fick LONDON (Reuters) -AstraZeneca said on Friday it ...

Q4 2025 Earnings Call February 10, 2026 6:45 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal ...